Logo image of COGT

COGENT BIOSCIENCES INC (COGT) Stock Fundamental Analysis

NASDAQ:COGT - Nasdaq - US19240Q2012 - Common Stock

8.225  +0.03 (+0.3%)

Fundamental Rating

3

Taking everything into account, COGT scores 3 out of 10 in our fundamental rating. COGT was compared to 572 industry peers in the Biotechnology industry. While COGT has a great health rating, there are worries on its profitability. COGT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year COGT has reported negative net income.
In the past year COGT has reported a negative cash flow from operations.
In the past 5 years COGT always reported negative net income.
In the past 5 years COGT always reported negative operating cash flow.
COGT Yearly Net Income VS EBIT VS OCF VS FCFCOGT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M -200M

1.2 Ratios

COGT's Return On Assets of -63.10% is on the low side compared to the rest of the industry. COGT is outperformed by 61.95% of its industry peers.
COGT has a Return On Equity (-77.00%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -63.1%
ROE -77%
ROIC N/A
ROA(3y)-46.38%
ROA(5y)-55%
ROE(3y)-54.41%
ROE(5y)-67.93%
ROIC(3y)N/A
ROIC(5y)N/A
COGT Yearly ROA, ROE, ROICCOGT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

COGT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
COGT Yearly Profit, Operating, Gross MarginsCOGT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K -2K

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for COGT has been increased compared to 1 year ago.
COGT has more shares outstanding than it did 5 years ago.
There is no outstanding debt for COGT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
COGT Yearly Shares OutstandingCOGT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
COGT Yearly Total Debt VS Total AssetsCOGT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

COGT has an Altman-Z score of 3.61. This indicates that COGT is financially healthy and has little risk of bankruptcy at the moment.
COGT has a Altman-Z score of 3.61. This is in the better half of the industry: COGT outperforms 77.88% of its industry peers.
There is no outstanding debt for COGT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.61
ROIC/WACCN/A
WACCN/A
COGT Yearly LT Debt VS Equity VS FCFCOGT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

COGT has a Current Ratio of 6.44. This indicates that COGT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of COGT (6.44) is better than 64.25% of its industry peers.
COGT has a Quick Ratio of 6.44. This indicates that COGT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 6.44, COGT is in the better half of the industry, outperforming 64.42% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.44
Quick Ratio 6.44
COGT Yearly Current Assets VS Current LiabilitesCOGT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for COGT have decreased by -6.44% in the last year.
EPS 1Y (TTM)-6.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

COGT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.57% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-3.25%
EPS Next 2Y0.91%
EPS Next 3Y8.28%
EPS Next 5Y17.57%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
COGT Yearly Revenue VS EstimatesCOGT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
COGT Yearly EPS VS EstimatesCOGT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for COGT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for COGT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
COGT Price Earnings VS Forward Price EarningsCOGT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
COGT Per share dataCOGT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.91%
EPS Next 3Y8.28%

More info and screens

0

5. Dividend

5.1 Amount

COGT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COGENT BIOSCIENCES INC

NASDAQ:COGT (1/22/2025, 1:06:33 PM)

8.225

+0.03 (+0.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners110.87%
Inst Owner Change0.74%
Ins Owners0%
Ins Owner Change5.66%
Market Cap908.53M
Analysts82.35
Price Target17.14 (108.39%)
Short Float %7.29%
Short Ratio5.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-6.73%
Min EPS beat(2)-10.87%
Max EPS beat(2)-2.6%
EPS beat(4)0
Avg EPS beat(4)-10.21%
Min EPS beat(4)-17.75%
Max EPS beat(4)-2.6%
EPS beat(8)1
Avg EPS beat(8)-8.9%
EPS beat(12)2
Avg EPS beat(12)-10.7%
EPS beat(16)3
Avg EPS beat(16)-75.49%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.67%
PT rev (3m)2.44%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.65%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.89
P/tB 2.89
EV/EBITDA N/A
EPS(TTM)-2.48
EYN/A
EPS(NY)-2.36
Fwd EYN/A
FCF(TTM)-1.74
FCFYN/A
OCF(TTM)-1.73
OCFYN/A
SpS0
BVpS2.85
TBVpS2.85
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -63.1%
ROE -77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.38%
ROA(5y)-55%
ROE(3y)-54.41%
ROE(5y)-67.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 33.57%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.44
Quick Ratio 6.44
Altman-Z 3.61
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)695.5%
Cap/Depr(5y)417.77%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-3.25%
EPS Next 2Y0.91%
EPS Next 3Y8.28%
EPS Next 5Y17.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-34.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-6.39%
EBIT Next 3Y-3.4%
EBIT Next 5YN/A
FCF growth 1Y-66.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-73.9%
OCF growth 3YN/A
OCF growth 5YN/A